Provided by Tiger Trade Technology Pte. Ltd.

HORIZON KINETICS MEDICAL ETF

35.29
+0.33190.95%
Post-market: 35.290.00000.00%16:10 EDT
Volume:227
Turnover:8K
Market Cap:16.58M
PE:- -
High:35.30
Open:35.30
Low:35.29
Close:34.96
52wk High:37.90
52wk Low:28.87
Shares:469.95K
Float Shares:469.95K
Volume Ratio:0.09
T/O Rate:0.05%
Dividend:0.41
Dividend Rate:1.16%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Johnson & Johnson to Present at Deutsche Bank 2026 Healthcare Summit

Reuters
·
Sep 03

Option traders moderately bearish in Eli Lilly with shareslittle changed

TIPRANKS
·
Sep 03

Sector Update: Healthcare

MT Newswires Live
·
Sep 03

H.C. Wainwright views Novartis, Alteogen pact as negative for Halozyme

TIPRANKS
·
Sep 03

Novartis AG Rises Wednesday, Outperforms Market

Dow Jones
·
Sep 03

Johnson & Johnson's Drug Pipeline Supports Growth Outlook, UBS Securities Says

MT Newswires Live
·
Sep 02

LIVE Markets-Wall Street Starts Slow, Dow Leads

Reuters
·
Sep 02

Johnson & Johnson Stock (JNJ) Opened Up by 3.15% on Sep 2: Key Drivers Unveiled

TradingKey
·
Sep 02

Johnson & Johnson, Boeing Share Gains Contribute to Dow's 250-Point Climb

Dow Jones
·
Sep 02

Aspen Bets on Manufacturing Rebound, Obesity Drug Push for Growth

Reuters
·
Sep 02

Allergan Aesthetics Unveils Layered Beauty Report on Global Shift Toward Personalized Aesthetic Care

Reuters
·
Sep 02

Shenzhen Regulator Launches 2026 Roadshow Selection for Key Medical Device Innovation Projects

Deep News
·
Sep 02

Johnson & Johnson assumed with a Buy at UBS

TIPRANKS
·
Sep 02

Novartis, Alteogen Sign Drug-Technology Deal Worth Up to $3.2 Billion

MT Newswires Live
·
Sep 02

Alteogen enters option, license agreement with Novartis

TIPRANKS
·
Sep 02

Johnson & Johnson : UBS Raises Target Price to $320 from $280

THOMSON REUTERS
·
Sep 02

Novartis Trial Suspensions to Have Limited Financial Impact

Dow Jones
·
Sep 02

Shinva Medical Secures Class II and III Device Approvals for Advanced Radiotherapy and Thoracoscopic Systems

Stock News
·
Sep 02

港股动态:今海医疗科技股价攀升逾4%,中期收益激增逾1.3倍,核心业务向高附加值医疗器械领域转型

Stock News
·
Sep 02

Betta Pharma's Hong Kong IPO: A Profit Pioneer Faces Patent Cliffs and Pipeline Doubts

Deep News
·
Sep 02